Temelimab as a Disease Modifying Therapy in Patients With Neuropsychiatric Symptoms in Long-COVID

https://clinicaltrials.gov/ct2/show/NCT05497089?term=temelimab&draw=2&rank=1

The GNC-501 study, entitled “Temelimab as a Disease Modifying Therapy in Patients with Neurological, Neuropsychological, and Psychiatric Symptoms in Post-COVID-19 or Post-Acute Sequelae of COVID-19 (PASC) Syndrome”, will enroll 200 patients from Swiss and EU study centres suffering from severe neuropsychiatric syndromes following COVID infection. The biomarker-based study will enrol only patients who are also tested positive for the pathogenic protein W-ENV, with the objective to reduce their invalidating conditions.

Current active sites:

SWITZERLAND

Geneva: Hôpital Universitaire de Genève - https://recherche.hug.ch/etudes/temelimab
Service de Premier Recours, Rue Gabrielle-Perret-Gentil 4, 1205 Genève.
Email: etude.longcovid@hcuge.ch

Basel: REHAB Basel Klinik für Neurorehabilitation und Paraplegiologie
Im Burgfelderhof 40, 4055 Basel
https://www.rehab.ch/en/medical-services/special-skills/post-covid-sprechstunde

Bern: INSELSPITAL, Neuroimmunological Study Centre (NIS)
Freiburgstrasse 14, SH2, EG3, 3010 Bern - http://www.NIS.insel.ch/

Chur: Kantonsspital Graubünden - https://www.ksgr.ch/long-covid-sprechstunde.aspx
Tel. +41 81 256 72 10

Sion: Hôpital du Valais– Centre hospitalier du Valais Romand -
Hôpital de Sion, Avenue du Grand-Champsec 80, 1950 Sion - Service de pneumologie
www.hopitalvs.ch/covid-long - www.hopitalvs.ch/pneumo - Marlène Salamin: +41 27 603 45 57

ITALY

Rome: U.O.C. Malattie Infettive Tor Vergata, Policlinico Tor Vergata
Contact: Loredana Sarmati, MD, Prf
Tel. +39-06.2090.3440 - email: malattie.infettive@ptvonline.postecert.it

SPAIN

Barcelona: Ace Alzheimer Center, Barcelona
Contact: Mercé Boada Rovira, MD